This information is intended for use by health professionals

1. Name of the medicinal product

Myocet liposomal 50 mg powder, dispersion and solvent for concentrate for dispersion for infusion.

2. Qualitative and quantitative composition

Liposome–encapsulated doxorubicin–citrate complex corresponding to 50 mg doxorubicin hydrochloride (HCl).

Excipient(s) with known effect: The reconstituted medicinal product contains approximately 108 mg sodium for a 50 mg doxorubicin HCl dose.

For the full list of excipients, see section 6.1.

3. Pharmaceutical form

Powder, dispersion and solvent for concentrate for dispersion for infusion

Myocet liposomal is supplied as a three-vial system as follows:

Vial 1 - doxorubicin HCl is a red lyophilised powder.

Vial 2 - liposomes is a white to off-white, opaque and homogeneous dispersion.

Vial 3 - buffer is a clear colourless solution.

4. Clinical particulars
4.1 Therapeutic indications

Myocet liposomal, in combination with cyclophosphamide, is indicated for the first line treatment of metastatic breast cancer in adult women.

4.2 Posology and method of administration

The use of Myocet liposomal should be confined to units specialised in the administration of cytotoxic chemotherapy and should only be administered under the supervision of a physician experienced in the use of chemotherapy.

Posology

When Myocet liposomal is administered in combination with cyclophosphamide (600 mg/m2) the initial recommended dose of Myocet liposomal is 60-75 mg/m2 every three weeks.

Older people

Safety and efficacy of Myocet liposomal have been assessed in 61 patients with metastatic breast cancer, age 65 and over. Data from randomised controlled clinical trials show that the efficacy and cardiac safety of Myocet liposomal in this population was comparable to that observed in patients less than 65 years old.

Patients with hepatic impairment

As metabolism and excretion of doxorubicin occurs primarily by the hepatobiliary route, evaluation of hepatobiliary function should be performed before and during therapy with Myocet liposomal.

Based on limited data in patients with liver metastases, it is recommended that the initial dose of Myocet liposomal is reduced in accordance with the following table

Liver function tests

Dose

Bilirubin < ULN and normal AST

Standard dose of 60 - 75mg/m2

Bilirubin < ULN and raised AST

Consider a 25% dose reduction

Bilirubin > ULN but < 50 μmol/l

50% dose reduction

Bilirubin > 50 μmol/l

75% dose reduction

If possible, Myocet liposomal should be avoided in patients with bilirubin > 50 μmol/l as the recommendation is based mainly on extrapolations.

For dose reductions due to other toxicity, see section 4.4.

Patients with renal impairment

Doxorubicin is metabolised largely by the liver and excreted in the bile. Therefore dose modification is not required for patients with renal function impairment.

Paediatric population

The safety and efficacy of Myocet liposomal in children aged up to 17 years has not been established. No data are available.

Method of administration

Myocet liposomal must be reconstituted and further diluted prior to administration. A final concentration of between 0.4 mg/ml to 1.2 mg/ml doxorubicin HCl, is required. Myocet liposomal is administered by intravenous infusion over a period of 1 hour.

Myocet liposomal must not be administered by the intramuscular or subcutaneous route or as a bolus injection.

For instructions on reconstitution of the medicinal product before administration, see section 6.6.

4.3 Contraindications

Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.

4.4 Special warnings and precautions for use

Myelosuppression

Therapy with Myocet liposomal causes myelosuppression. Myocet liposomal should not be administered to individuals with absolute neutrophil counts (ANC) lower than 1,500 cells/μl or platelets less than 100,000/μl prior to the next cycle. Careful haematological monitoring (including white blood cell and platelet count, and haemoglobin) should be performed during therapy with Myocet liposomal.

A meta-analysis showed a statistically significant lower rate of grade 4 neutropenia (RR = 0.82, p=0.005) in patients treated with Myocet liposomal versus conventional doxorubicin. However, no significant differences were identified in the occurrence of anaemia, thrombocytopenia and episodes of neutropenic fever.

Haematological as well as other toxicity may require dose reductions or delays. The following dosage modifications are recommended during therapy and should be performed in parallel for both Myocet liposomal and cyclophosphamide. Dosing subsequent to a dose reduction is left to the discretion of the physician in charge of the patient.

Haematological Toxicity

Grade

Nadir ANC

(cells/μl)

Nadir Platelet Count

(cells/μl)

Modification

1

1500 – 1900

75,000 – 150,000

None

2

1000 – Less than 1500

50,000 – Less than 75,000

None

3

500 – 999

25,000 – Less than 50,000

Wait until ANC 1500 or more and/or platelets 100,000 or more then redose at 25% dose reduction

4

Less than 500

Less than 25,000

Wait until ANC 1500 and/or platelets 100,000 or more then redose at 50% dose reduction

If myelotoxicity delays treatment to greater than 35 days after the first dose of the previous cycle, then consideration should be given to stopping treatment.

Mucositis

Grade

Symptoms

Modification

1

Painless ulcers, erythema, or mild soreness.

None

2

Painful erythema, oedema or ulcers but can eat.

Wait one week and if the symptoms improve redose at 100% dose

3

Painful erythema, oedema or ulcers and cannot eat

Wait one week and if symptoms improve redose at 25% dose reduction

4

Requires parenteral or enteral support

Wait one week and if symptoms improve redose at 50% dose reduction

For dose reduction of Myocet liposomal due to liver function impairment, see section 4.2.

Cardiac toxicity

Doxorubicin and other anthracyclines can cause cardiotoxicity. The risk of toxicity rises with increasing cumulative doses of those medicinal products and is higher in individuals with a history of cardiomyopathy, or mediastinal irradiation or pre-existing cardiac disease.

Analyses of cardiotoxicity in clinical trials have shown a statistically significant reduction in cardiac events in patients treated with Myocet liposomal compared to patients treated with conventional doxorubicin at the same dose in mg. A meta-analysis showed a statistically significant lower rate of both clinical heart failure (RR = 0.20, p=0.02) and clinical and subclinical heart failure combined (RR = 0.38, p<0.0001) in patients treated with Myocet liposomal versus conventional doxorubicin. The reduced risk of cardiotoxicity has also been shown in a retrospective analysis in patients who had received prior adjuvant doxorubicin (log-rank P=0.001, Hazard Ratio=5.42).

In a phase III study in combination with cyclophosphamide (CPA) comparing Myocet liposomal (60 mg/m2) + CPA (600 mg/m2) versus doxorubicin (60 mg/m2) + CPA (600 mg/m2), 6% versus 21% of patients, respectively, developed a significant decrease in left ventricular ejection fraction (LVEF). In a phase III study comparing single-agent Myocet liposomal (75 mg/m2) versus single-agent doxorubicin (75 mg/m2), 12% versus 27% of patients, respectively developed a significant decrease in LVEF. The corresponding figures for congestive heart failure, which was less accurately assessed, were 0% for Myocet liposomal + CPA versus 3% for doxorubicin + CPA, and 2% for Myocet liposomal versus 8% for doxorubicin. The median lifetime cumulative dose of Myocet liposomal in combination with CPA to a cardiac event was > 1260 mg/m2, compared to 480 mg/m2 for doxorubicin combination with CPA.

There is no experience with Myocet liposomal in patients with a history of cardiovascular disease, e.g. myocardial infarction within 6 months prior to treatment. Thus, caution should be exercised in patients with impaired cardiac function. The cardiac function of the patients treated concomitantly with Myocet liposomal and trastuzumab must be appropriately monitored as described below.

The total dose of Myocet liposomal should also take into account any previous, or concomitant, therapy with other cardiotoxic compounds, including anthracyclines and anthraquinones.

Before initiation of Myocet liposomal therapy a measurement of left ventricular ejection fraction (LVEF) is routinely recommended, either by Multiple Gated Arteriography (MUGA) or by echocardiography. These methods should also be applied routinely during Myocet liposomal treatment. The evaluation of left ventricular function is considered mandatory before each additional administration of Myocet liposomal once a patient exceeds a lifetime cumulative anthracycline dose of 550 mg/m2 or whenever cardiomyopathy is suspected. If LVEF has decreased substantially from baseline e.g. by > 20 points to a final value > 50% or by > 10 points to a final value of < 50%, the benefit of continued therapy must be carefully evaluated against the risk of producing irreversible cardiac damage. However, the most definitive test for anthracycline myocardial injury, i.e., endomyocardial biopsy, should be considered.

All patients receiving Myocet liposomal should also routinely undergo ECG monitoring. Transient ECG changes such as T-wave flattening, S-T segment depression and benign arrhythmias are not considered mandatory indications for the cessation of Myocet liposomal therapy. However, reduction of the QRS complex is considered more indicative of cardiac toxicity.

Congestive heart failure due to cardiomyopathy may occur suddenly, and may also be encountered after discontinuation of therapy.

Gastroinstestinal disorders

A meta-analysis showed a statistically significant lower rate of nausea/vomiting grade ≥ 3 (RR = 0.65, p=0.04) and diarrhoea grade ≥ 3(RR = 0.33, p=0.03) in patients treated with Myocet liposomal versus conventional doxorubicin.

Injection site reactions

Myocet liposomal should be considered an irritant and precautions should be taken to avoid extravasation. If extravasation occurs, the infusion should be immediately terminated. Ice may be applied to the affected area for approximately 30 minutes. Subsequently, the Myocet liposomal infusion should be restarted in a different vein than that in which the extravasation has occurred. Note that Myocet liposomal may be administered through a central or peripheral vein. In the clinical program, there were nine cases of accidental extravasation of Myocet liposomal, none of which were associated with severe skin damage, ulceration or necrosis.

Infusion associated reactions

When infused rapidly acute reactions associated with liposomal infusions have been reported. Reported symptoms have included flushing, dyspnoea, fever, facial swelling, headache, back pain, chills, tightness in the chest and throat, and/or hypotension. These acute phenomena may be avoided by using a 1-hour infusion time.

Other

For precautions regarding the use of Myocet liposomal with other medicinal products, see section 4.5.

As for other anthracyclines and doxorubicin products, radiation recall may occur in previously irradiated fields.

Efficacy and safety of Myocet liposomal in the adjuvant treatment of breast cancer have not been determined. The importance of apparent differences in tissue distribution between Myocet liposomal and conventional doxorubicin has not been elucidated with respect to long-term antitumour efficacy.

4.5 Interaction with other medicinal products and other forms of interaction

Specific medicinal product compatibility studies have not been performed with Myocet liposomal. Myocet liposomal is likely to interact with substances that are known to interact with conventional doxorubicin. Plasma levels of doxorubicin and its metabolite, doxorubicinol, may be increased when doxorubicin is administered with cyclosporin, verapamil, paclitaxel or other agents that inhibit P-glycoprotein (P-Gp). Interactions with doxorubicin have also been reported for streptozocin, phenobarbital, phenytoin and warfarin. Studies of the effect of Myocet liposomal on other substances are also lacking. However, doxorubicin may potentiate the toxicity of other antineoplastic agents. Concomitant treatment with other substances reported to be cardiotoxic or with cardiologically active substances (e.g. calcium antagonists) may increase the risk for cardiotoxicity. Concomitant therapy with other liposomal or lipid-complexed substances or intravenous fat emulsions could change the pharmacokinetic profile of Myocet liposomal.

4.6 Fertility, pregnancy and lactation

Women of childbearing potential

Women of childbearing potential should use an effective contraceptive during treatment with Myocet liposomal and up to 6 months following discontinuation of therapy.

Pregnancy

Due to the known cytotoxic, mutagenic and embryotoxic properties of doxorubicin, Myocet liposomal should not be used during pregnancy unless clearly necessary.

Breast-feeding

Women receiving Myocet liposomal should not breastfeed.

4.7 Effects on ability to drive and use machines

Myocet liposomal has been reported to cause dizziness. Patients who suffer from this should avoid driving and operating machinery.

4.8 Undesirable effects

During clinical trials, the most frequently reported adverse reactions were nausea/vomiting (73%), leucopoenia (70%), alopecia (66%), neutropenia (46%), asthenia/fatigue (46%), stomatitis/mucositis (42%), thrombocytopenia (31%) and anaemia (30%).

The following adverse reactions have been reported with Myocet liposomal during clinical studies and post marketing experience. Adverse reactions are listed below as MedDRA preferred term by system organ class and frequency (frequencies are defined as: very common ≥1/10, common ≥1/100 to <1/10, uncommon ≥ 1/1,000 to <1/100, not known (cannot be estimated from the available data).

 

All grades

Grades ≥ 3

Infections and infestations

Neutropenic fever

Very common

Very common

Infections

Very common

Common

Herpes zoster

Uncommon

Uncommon

Sepsis

Uncommon

Uncommon

Injection site infection

Uncommon

Not known

Blood and lymphatic system disorders

Neutropenia

Very common

Very common

Thrombocytopenia

Very common

Very common

Anaemia

Very common

Very common

Leucopenia

Very common

Very common

Lymphopenia

Common

Common

Pancytopenia

Common

Uncommon

Neutropenic sepsis

Uncommon

Uncommon

Purpura

Uncommon

Uncommon

Metabolism and nutrition disorders

Anorexia

Very common

Very common

Dehydration

Common

Very common

Hypokalaemia

Common

Uncommon

Hyperglycaemia

Uncommon

Uncommon

Psychiatric disorders

Agitation

Uncommon

Not known

Nervous system disorders

Insomnia

Common

Uncommon

Abnormal gait

Uncommon

Uncommon

Dysphonia

Uncommon

Not known

Somnolence

Uncommon

Not known

Cardiac disorders

Arrhythmia

Common

Uncommon

Cardiomyopathy

Common

Common

Congestive cardiac failure

Common

Common

Pericardial effusion

Uncommon

Uncommon

Vascular disorders

Hot flushes

Common

Uncommon

Hypotension

Uncommon

Uncommon

Respiratory, thoracic and mediastinal disorders

Chest pain

Common

Uncommon

Dyspnoea

Common

Uncommon

Epistaxis

Common

Uncommon

Haemoptysis

Uncommon

Not known

Pharyngitis

Uncommon

Not known

Pleural effusion

Uncommon

Uncommon

Pneumonitis

Uncommon

Uncommon

Gastrointestinal disorders

Nausea/vomiting

Very common

Very common

Stomatitis/mucositis

Very common

Common

Diarrhoea

Very common

Common

Constipation

Common

Uncommon

Oesophagitis

Common

Uncommon

Gastric ulcer

Uncommon

Uncommon

Hepato-biliary disorders

Increased hepatic transaminases

Common

Uncommon

Increased alkaline phosphatase

Uncommon

Uncommon

Jaundice

Uncommon

Uncommon

Increased serum bilirubin

Uncommon

Not known

Skin and subcutaneous tissue disorders

Alopecia

Very Common

Common

Rash

Common

Not known

Palmar-plantar erythrodysaesthesia syndrome

Not known

Not known

Nail disorder

Common

Uncommon

Pruritus

Uncommon

Uncommon

Folliculitis

Uncommon

Uncommon

Dry skin

Uncommon

Not known

Musculoskeletal, connective tissue and bone disorders

Back pain

Common

Uncommon

Myalgia

Common

Uncommon

Muscle weakness

Uncommon

Uncommon

Renal and urinary disorders

Haemorrhagic cystitis

Uncommon

Uncommon

Oliguria

Uncommon

Uncommon

General disorders and administration site conditions

Asthenia/Fatigue

Very Common

Common

Fever

Very common

Common

Pain

Very Common

Common

Rigors

Very Common

Uncommon

Dizziness

Common

Uncommon

Headache

Common

Uncommon

Weight loss

Common

Uncommon

Injection site reaction

Uncommon

Uncommon

Malaise

Uncommon

Not known

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.

4.9 Overdose

Acute overdose with Myocet liposomal will worsen toxic side effects. Treatment of acute overdose should focus on supportive care for expected toxicity and may include hospitalisation, antibiotics, platelet and granulocyte transfusions and symptomatic treatment of mucositis.

5. Pharmacological properties
5.1 Pharmacodynamic properties

Pharmaco-therapeutic group: Antineoplastic agents, anthracyclines and related substances, ATC code: L01DB01

The active substance in Myocet liposomal is doxorubicin HCl. Doxorubicin may exert its antitumour and toxic effects by a number of mechanisms including inhibition of topoisomerase II, intercalation with DNA and RNA polymerases, free radical formation and membrane binding. Liposomal-encapsulated doxorubicin compared with conventional doxorubicin was not found more active in doxorubicin resistant cell lines in vitro. In animals, liposome-encapsulated doxorubicin reduced the distribution to heart and gastrointestinal mucosa compared with conventional doxorubicin, while antitumoural efficacy in experimental tumours was maintained.

Myocet liposomal (60 mg/m2) + CPA (600 mg/m2) was compared with conventional doxorubicin + CPA (at the same doses) and Myocet liposomal (75 mg/m2) + CPA (600 mg/m2) was compared to epirubicin + CPA (at the same doses). In a third trial, Myocet liposomal (75 mg/m2) monotherapy was compared with conventional doxorubicin monotherapy (at the same dose). Findings regarding response rate and progression-free survival are provided in Table 3.

Table 3

Antitumour efficacy summary for combination and single-agent studies

 

Myocet liposomal/CPA

(60/600 mg/m2)

(n=142)

Dox 60/CPA (60/600 mg/m2)

(n=155)

Myocet liposomal/CPA

(75/600 mg/m2)

(n=80)

Epi/CPA

(75/600 mg/m2)

(n=80)

Myocet liposomal

(75 mg/m2)

(n=108)

Dox

(75 mg/m2)

(n=116)

Tumour response rate

43%

43%

46%

39%

26%

26%

Relative Risk

(95% C.I.)

1.01

(0.78-1.31)

1.19

(0.83-1.72)

1.00

(0.64-1.56)

Median PFS (months)a

5.1

5.5

7.7

5.6

2.9

3.2

Risk Ratio

(95% C.I.)

1.03

(0.80-1.34)

1.52

(1.06-2.20)

0.87

(0.66-1.16)

Abbreviations: PFS, progression-free survival; Dox, doxorubicin; Epi, epirubicin; Relative Risk, comparator taken as reference; Risk Ratio, Myocet liposomal taken as reference

a Secondary endpoint

5.2 Pharmacokinetic properties

The plasma pharmacokinetics for total doxorubicin in patients receiving Myocet liposomal shows a high degree of inter-patient variability. In general however, the plasma levels of total doxorubicin are substantially higher with Myocet liposomal than with conventional doxorubicin, while the data indicate that peak plasma levels of free (not liposome-encapsulated) doxorubicin are lower with Myocet liposomal than with conventional doxorubicin. Available pharmacokinetic data preclude conclusions regarding the relationship between plasma levels of total/free doxorubicin and its influence on the efficacy/safety of Myocet liposomal. The clearance of total doxorubicin was 5.1 ± 4.8 l/h and the volume of distribution at steady state (Vd) was 56.6 ± 61.5 l whereas after conventional doxorubicin, clearance and Vd were 46.7 ± 9.6 l/h and 1,451 ± 258 l, respectively. The major circulating metabolite of doxorubicin, doxorubicinol, is formed via aldo-keto-reductase. The peak levels of doxorubicinol occur in the plasma later with Myocet liposomal than with conventional doxorubicin.

The pharmacokinetics of Myocet liposomal have not been specifically studied in patients with renal insufficiency. Doxorubicin is known to be eliminated in large part by the liver. A dose reduction of Myocet liposomal has been shown to be appropriate in patients with impaired hepatic function (see section 4.2 for dosage recommendations).

Substances that inhibit P-glycoprotein (P-Gp) have been shown to alter the disposition of doxorubicin and doxorubicinol (see also section 4.5).

5.3 Preclinical safety data

Studies of genotoxicity, carcinogenicity and reproductive toxicity of Myocet liposomal have not been performed but doxorubicin is known to be both mutagenic and carcinogenic and may cause toxicity to reproduction.

6. Pharmaceutical particulars
6.1 List of excipients

Vial 1 - doxorubicin HCl

• lactose

Vial 2 - liposomes

• phosphatidylcholine

• cholesterol

• citric acid

• sodium hydroxide

• water for injections

Vial 3 - buffer

• sodium carbonate

• water for injections

6.2 Incompatibilities

This medicinal product must not be mixed with other medicinal products except those mentioned in section 6.6.

6.3 Shelf life

18 months

Chemical and physical in-use stability after reconstitution has been demonstrated for up to 8 hours at 25°C, and for up to 5 days at 2°C – 8οC.

From a microbiological point of view, the medicinal product should be used immediately. If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and would normally not be longer than 24 hours at 2οC – 8οC, unless reconstitution and dilution has taken place in controlled and validated aseptic conditions.

6.4 Special precautions for storage

Store in a refrigerator (2°C – 8°C).

For storage conditions after reconstitution of the medicinal product, see section 6.3.

6.5 Nature and contents of container

Myocet liposomal is available in cartons containing 1 set or 2 sets of the three constituent vials. Not all pack-sizes may be marketed.

Vial 1 - doxorubicin HCl

Type I glass vials sealed with grey butyl rubber stoppers and orange flip-off aluminium seals, containing 50 mg of doxorubicin HCl lyophilised powder.

Vial 2 - liposomes

Type I flint glass tubing vials sealed with siliconised grey stopper and green flip-off aluminium seals, containing not less than 1.9 ml of liposomes.

Vial 3 - buffer

Glass vials sealed with siliconised grey stopper and blue aluminium flip-off seals, containing not less than 3 ml of buffer.

6.6 Special precautions for disposal and other handling

Preparation of Myocet liposomal

Aseptic technique must be strictly observed throughout handling of Myocet liposomal, since no preservative is present.

Caution should be exercised in the handling and preparation of Myocet liposomal. The use of gloves is required

Step 1. Set up

Two alternative heating methods can be used : a Techne DB-3 Dri Block heater or a water bath:

• Turn on the Techne DB-3 Dri Block heater and set the controller to 75°C-76°C. Verify the temperature set point by checking the thermometer(s) on each heat block insert.

• If using a water bath, turn on the water bath and allow it to equilibrate at 58°C (55°C-60°C). Verify the temperature set point by checking the thermometer.

(Please note that whilst the control settings on the water bath and heat block are set to different levels the temperature of the vial contents are in the same range (55°C-60°C)).

Remove the carton of constituents from the refrigerator.

Step 2. Reconstitute doxorubicin HCl

• Withdraw 20 ml sodium chloride solution for injection (0.9%), (not provided in the package), and inject into each vial of doxorubicin HCl, intended for preparation.

• Shake well in the inverted position to ensure doxorubicin is fully dissolved.

Step 3. Heat in water bath or dry heat block

• Heat the reconstituted doxorubicin HCl vial in the Techne DB-3 Dri Block heater with the thermometer in the block reading (75°C-76°C) for 10 minutes (not to exceed 15 minutes). If using a water bath, heat the doxorubicin HCl vial with the thermometer temperature reading 55°C-60°C for 10 minutes (not to exceed 15 minutes).

• While heating proceed to step 4

Step 4. Adjust Ph of liposomes

• Withdraw 1.9 ml of liposomes. Inject into the buffer vial to adjust the Ph of liposomes. Pressure build-up may require venting.

• Shake well.

Step 5. Add Ph-adjusted liposomes to doxorubicin

• Using a syringe, withdraw the entire vial contents of Ph-adjusted liposomes from the buffer vial.

• Remove the reconstituted doxorubicin HCl vial from the water bath or dry heat block. SHAKE VIGOROUSLY. Carefully insert a pressure-venting device equipped with a hydrophobic filter. Then IMMEDIATELY (within 2 minutes) inject Ph-adjusted liposomes into vial of heated reconstituted doxorubicin HCl. Remove venting device.

• SHAKE VIGOROUSLY.

• WAIT for a minimum of 10 MINUTES before using, keeping the medicine at room temperature.

• The Techne DB-3 Dri Block Heater is fully validated for use in the constitution of Myocet liposomal. Three inserts, each with two 43.7mm openings per insert must be used. To ensure correct temperature control the use of a 35mm immersion thermometer is recommended.

The resulting reconstituted preparation of Myocet liposomal contains 50 mg of doxorubicin HCl/25 ml of liposomal dispersion (2 mg/ml).

After reconstitution the finished product must be further diluted in 0.9% (w/v) sodium chloride for injection, or 5% (w/v) glucose solution for injection to a final volume of 40 ml to 120 ml so that a final concentration of 0.4 mg/ml to 1.2 mg/ml doxorubicin is obtained.

Once constituted, the liposomal dispersion for infusion containing liposome-encapsulated doxorubicin should be a red orange opaque homogeneous dispersion. All parenteral solutions should be inspected visually for particulate matter and discoloration prior to administration. Do not use the preparation if foreign particulate matter is present.

Procedure for proper disposal

Any unused medicinal product or waste material should be disposed of in accordance with local requirements.

7. Marketing authorisation holder

TEVA B.V.

Swensweg 5

2031 GA Haarlem

Netherlands

8. Marketing authorisation number(s)

EU/1/00/141/001-002

9. Date of first authorisation/renewal of the authorisation

Date of first authorisation: 13 July 2000

Date of latest renewal: 02 July 2010

10. Date of revision of the text

10/2019

Detailed information on this product is available on the website of the European Medicines Agency http://www.ema.europa.eu.